- Src-dependent activation of the mTOR signaling in melanoma cells2012 | First Faculty of Medicine
- Activity of c-Src as a novel target for the inhibition of mTOR signaling in human diseasesPublication without faculty affiliation
- CAS mediates crosstalk of Src and mTOR signalingPublication without faculty affiliation
- MTOR - the atractive and mysterious signal proteinPublication without faculty affiliation
- Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes2021 | Third Faculty of Medicine
- Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021)2022 | Publication without faculty affiliation
- Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)2023 | Publication without faculty affiliation
- Metformin – a new star in cancer treatment?2012 | First Faculty of Medicine
- Quambalarine B, a Secondary Metabolite from Quambalaria cyanescens with Potential Anticancer Properties2016 | Faculty of Science
- A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse2019 | First Faculty of Medicine
- Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma2020 | First Faculty of Medicine
- Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway2014 | Faculty of Medicine in Pilsen
- Comprehensive Analysis of PTEN in Primary Cutaneous Melanoma2020 | First Faculty of Medicine
- The requirements for dasatinib sensitivity in human melanoma cell lines2014 | First Faculty of Medicine
- Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression2016 | Second Faculty of Medicine
- The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury2023 | Second Faculty of Medicine
- Frentizole derivatives with mTOR inhibiting and senomorphic properties2023 | Third Faculty of Medicine
